Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Insights and modulation of RNA polymerase–dependent R-loop and dsRNA in Fanconi anemia hematopoietic stem cells
Michihiro Hashimoto, Xiaomin Feng, Jie Bai, Huimin Zeng, Tian Li, Jue Li, Terumasa Umemoto, Paul R. Andreassen, Gang Huang
Michihiro Hashimoto, Xiaomin Feng, Jie Bai, Huimin Zeng, Tian Li, Jue Li, Terumasa Umemoto, Paul R. Andreassen, Gang Huang
View: Text | PDF
Research Article Cell biology Hematology

Insights and modulation of RNA polymerase–dependent R-loop and dsRNA in Fanconi anemia hematopoietic stem cells

  • Text
  • PDF
Abstract

Fanconi anemia (FA) is the most common BM failure (BMF) syndrome. FA genes have a role in suppressing DNA-RNA hybrids, termed R-loops, which can be generated via transcription mediated by RNA polymerase (RNAP). How these processes, including a role in fate determination of hematopoietic stem cells (HSCs), are related to BMF is largely unknown. Single FA gene KO in mice does not recapitulate most phenotypes observed in patients with FA. Thus, we generated a mouse model for FA by introducing heterozygous Setd2, which restricts RNAP-dependent transcription. We showed that FA patient–derived cells and Setd2+/– Fanca–/– HSCs share increased R-loop and dsRNA levels and a ribosomal biogenesis defect. Further, Setd2+/– Fanca–/– HSCs displayed cell cycle arrest, mitotic errors, and BMF phenotypes. Importantly, utilizing our Setd2+/– Fanca–/– mice, we discovered that Juglone, a pan-RNAP inhibitor, reduces R-loop and dsRNA and reverses ribosomal biogenesis defects and mitotic errors, thereby rescuing BMF. This study establishes a mouse model that underscores a key role for R-loop formation, ribosomal biogenesis defects, and mitotic errors in HSCs in driving BMF in FA. We also introduce a potential therapeutic avenue based upon pan-inhibition of RNAPs utilizing Juglone.

Authors

Michihiro Hashimoto, Xiaomin Feng, Jie Bai, Huimin Zeng, Tian Li, Jue Li, Terumasa Umemoto, Paul R. Andreassen, Gang Huang

×

Figure 6

Treatment with Juglone slows cell division and facilitates the maintenance of stemness and improves engraftment of Setd2+/– Fanca–/– HSCs.

Options: View larger image (or click on image) Download as PowerPoint
Treatment with Juglone slows cell division and facilitates the maintenan...
(A and B) Proliferation capacity counted by Celigo (A) and HSC frequency analyzed by flow cytometry (B) of WT control or Setd2+/– Fanca–/– HSCs after 5 days of liquid culture. N = 3 each condition. (C) Single-cell culture of control or Setd2+/– Fanca–/– cells with or without Juglone (0.1 µM) for 2 days. Cell numbers per well counted at day 2. N = 3 for each condition. (D–G) Cell division history analysis of control and Setd2+/– Fanca–/– HSCs with or without Juglone (0.1 µM). HSCs were sorted, labeled with CytoTell Green, and cultured for 5 days before analysis by flow cytometry. Representative CytoTell plots (D) and quantification of high (E), medium (F), and low (G) division histories are shown. N = 3 for each condition. (H) Mitotic errors (binucleated or micronucleated cells) in Setd2+/– Fanca–/– HSCs after 5 days of Juglone treatment (0.1 µM) in liquid culture. N = 3 for each condition. (I) Experimental scheme of BM transplantation with drug-treated HSPCs. (J) BM transplantation of control (black) and Setd2+/– Fanca–/– (red) HSCs, with or without Juglone treatment. Engraftment was measured as the percentage of CD45.2+ PB cells at 4, 8, and 12 weeks. N = 5 for each condition. (K) Secondary transplantation of control (black) and Setd2+/– Fanca–/– (red) BMCs, with or without Juglone treatment; engraftment measured as CD45.2+ PB cells at 10 weeks. N = 4 for each condition. (L) Experimental scheme of Juglone in vivo treatment. (M and N) Total BMC numbers (M) and absolute HSC numbers (N) in control (black) and Setd2+/– Fanca–/– (red) mice with or without Juglone treatment. N = 3 for each point. Data are shown as mean ± SEM. Statistical significance was determined by 1-way ANOVA with Tukey’s multiple-comparison test unless otherwise indicated; panel J was analyzed by 2-way ANOVA with Tukey’s multiple-comparison test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts